Bone Biologics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2 Burlington Woods Dr Ste 100, Burlingto...Phone Number
(781) 552-4452Website
www.bonebiologics.comRevenue
-Stock Symbol
BBLGIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Bone Biologics
A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA. Bone Biologics market and focus is in the Regenerative Medicine Orthobiologics space. Bone Biologics was founded in 2004 by University of California professors in collaboration with an Osaka University professor and a USC surgeon and acquired in 2006 by MTF as the major shareholder, who has been the primary funder since the acquisition. The Companys proprietary, patented platform technology UCB-1, exclusively licensed from UCLA, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and Rhesus Monkey) studies that have demonstrated that the UCB-1 technology facilitates superior normal bone growth. The company believes that as a platform technology, UCB-1 has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bone Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Bone Biologics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Bone Biologics
Earning: See what the market has to say on Bone Biologics recently announced quarterly report
Funding: Get notified immidiatlly once Bone Biologics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Bone Biologics had a recent Job posting/layoffs
Check if Bone Biologics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Bone Biologics launches new products
Website visits: Recent activity has been detected on your website
Bone Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Bone Biologics
Find 2 more new buyers
Compare Similar Companies to Bone Biologics
Compare insights from companies similar to Bone Biologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Bone Biologics
1-10
Public
$16.1M
2004
N/A
Company Profile Activity
Activity Insights
Bone Biologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bone Biologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bone Biologics.
Bone Biologics financials insights
Gather financial insights about Bone Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$16.1M
Bone Biologics Tech Stack
A closer look at the technologies used by Bone Biologics
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
Person-Based
Bone Biologics News & Media
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
BURLINGTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
Milestone strengthens manufacturing flexibility and supports pivotal study readiness Milestone strengthens manufacturing flexibility and supports pivotal study readinessBone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027 Strengthened capital position supports continued advancement of NB1 clinical development, manufacturing readiness and intellectual property initiatives through Q2 2027Bone Biologics prices $3M private placement - BBLG - Stock Titan
The at-the-market deal includes 2.1M shares plus warrants at $1.42. Proceeds are slated for clinical trials, patents and working capital.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bone Biologics
Sign Up For FreeTo access detailed company insights
A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA. Bone Biologics market and focus is in the Regenerative Medicine Orthobiologics space. Bone Biologics was founded in 2004 by University of California professors in collaboration with an Osaka... Read More
